GlassScriptPhysician profile
Nadeem Hussain
NPI 1548228596
$12,728.75
in general payments reported to CMS, 2019-2025
46 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $660 · 2021: $2,069 · 2022: $2,696 · 2023: $2,186 · 2024: $1,862 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,246 · Education: $43.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,246.27 |
| Education | $43.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,150.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,708.67 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,342.85 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $902.89 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $816.49 | 2019-2025 | Livdelzi |
| Celgene Corporation | $616.09 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $520.23 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $425.97 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $425.94 | 2022-2025 | Dupixent |
| Olympus America INC. | $350.00 | 2020 | |
| Pfizer INC. | $261.93 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $213.48 | 2019-2024 | Ocaliva |
| Boston Scientific Corporation | $212.96 | 2021-2025 | Captivator II |
| Ironwood Pharmaceuticals, INC | $203.60 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $194.04 | 2021-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $185.53 | 2021-2023 | |
| Redhill Biopharma INC. | $157.32 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $147.17 | 2023 | Terlivaz |
| Pentax of America, INC. | $141.37 | 2022 | |
| Lucid Diagnostics INC. | $130.36 | 2022-2023 | |
| Allergan, INC. | $124.39 | 2019-2020 | |
| Celltrion USA INC. | $113.90 | 2024-2025 | Vegzelma, Zymfentra |
| Janssen Scientific Affairs, LLC | $109.02 | 2019 | |
| Genzyme Corporation | $105.28 | 2023-2024 | |
| Exact Sciences Corporation | $98.46 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $93.31 | 2019-2021 | |
| Ethicon US, LLC | $91.59 | 2022-2025 | Linx Reflux Management System |
| Aimmune Therapeutics, INC. | $91.49 | 2025 | Zenpep |
| Medtronic, INC. | $89.61 | 2022-2025 | Beacon |
| Ipsen Biopharmaceuticals, INC | $83.20 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $81.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $67.77 | 2023 | Renflexis, Hadlima |
| Novo Nordisk INC | $62.05 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $61.27 | 2021-2023 | Rebyota |
| Braintree Laboratories, INC. | $55.28 | 2024-2025 | Sutab, Suflave |
| Amgen INC. | $53.63 | 2022 | |
| Phathom Pharmaceuticals, INC. | $50.36 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $38.58 | 2024 | Omvoh |
| Otsuka America Pharmaceutical, INC. | $29.94 | 2022 | |
| Ucb, INC. | $22.22 | 2019 | |
| Alfasigma USA, INC. | $19.38 | 2020 | |
| Portola Pharmaceuticals, LLC | $17.12 | 2019 | |
| Capsovision, INC. | $16.47 | 2024 | Capsocam Plus |
| Shionogi INC | $16.24 | 2020 | |
| Laborie Medical Technologies Corp. | $16.01 | 2024 | Alphaone |
| Endogastric Solutions, INC | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.